Results with Lifescozul™Multiple Myeloma
Introduction to the case
Multiple myeloma is a cancer that affects plasma cells, which are located in the bone marrow and form a vital part of the immune system.
When plasma cells are affected and change and grow out of control, it is called multiple myeloma.
It is normal for patients to turn to the LifEscozul Protocol (escozul, blue scorpion venom) as a last resort, when conventional treatments can no longer do anything.
This is the case of Juana, who came to us with advanced metastasis and generalized pain, and despite the chemotherapy she was receiving, she was not having positive results.
Juana arrived at LifEscozul Group in September 2016. She has been with us for 4 years and her results have been impactful.
At this point, LifEscozul treatment, the most effective formulation made with blue scorpion venom, has become the difference."
Juana Gaytán Ortiz, 64 years old at the beginning of treatment with LifEscozul.
Generalized bone pain, more marked in the right hip, loss of appetite, insomnia, hot flashes, physical wasting, hair loss, eye weakness and pain, muscle numbness (in hands), pain, swelling and burning in the hip.
Multiple myeloma (diagnosed by bone marrow infiltration of abnormal plasma cells), with multiple bone lesions in cervical and lumbar spine and pelvic bones (largest lesion in coxal bone 50x25mm, plasmacytoma).
Right inguinal adenopathy.
Tumor at the level of the right clavicle.
In 2016, Juana went to the doctor due to persistent pain in the right clavicle and general bone pain.
She was diagnosed with multiple myeloma and the presence of bone metastasis was detected in several areas.
She immediately started chemotherapy and progressively presented a degradation of her quality of life, expressed in hair loss, weakness, pain and swelling.
However, the disease could not be controlled, the lesions multiplied and his quality of life practically disappeared.
In October 2016 we were contacted for an assessment with our Medical Group, being accepted the case in the Protocol, proposing a progressive treatment of LifEscozul, seeking an immediate response in the quality of life.
At that point we feared we did not have the necessary time to reverse the situation.
Evolution with LifEscozul™ and actual results
The specialized medical follow-up was activated the same day the medication was sent. Mrs. Juana's daughter is the one who has been in constant contact with our team of specialists during the treatment period, sending regular updates on her mother's condition.
In January 2017, 3 months after starting LifEscozul, she refers us that Juana is evolving very well.
She told us that the doctors in her country informed them that the marrow was now clear of malignant cells. She had recovered her appetite but symptoms of tiredness, numbness in her hands and bone pain persisted.
By April 2017, the daughter tells us that Juana was feeling well in general, with fatigue and pain in the pelvis at times.
At that time the best news of all was that the lump at the right clavicle level had disappeared.
In October 2017 we are informed that everything was still fine and Juana presented only discomfort in the pelvis area.
In parallel to these reports we began to increase the dose of LifEscozul, already focused on controlling the rest of the metastases.
The February 2018 report indicates that there are still bone lesions in the spine and sacral region, but the studies were not comparative and did not offer specific data in terms of lesion size and more precise location that would allow a comparison.
In June 2018 new myeloma activity was referred and it was decided to increase the dose of LifEscozul.
In July 2018 the bony lesion in the sacro coccygeal area measured 37x19mm, having decreased in size from the initial 50x25mm.
During the following months the information about Juana is that everything remained stable and that she was in good physical condition.
In May 2019 she was assessed for Autologous Marrow Transplant which was subsequently performed.
The tests we subsequently received showed no significant alterations, and Juana continued in good physical condition.
At the end of 2019 the tumor in the pelvis had also disappeared.
This year 2020, in all the controls Juana has maintained her quality of life and control over her disease.
The presence of metastases will always be a factor to consider when treating a patient.
Pain, its intensity and location also have an impact because nothing affects a patient's quality of life and therefore their emotional state as much as pain.
In Juana's case we had these two negative factors, which made us fear that we were not going to have time to achieve a good result.
The initial proposed dose of LifEscozul (escozul, blue scorpion venom) proved to be effective from the beginning, reducing pain and establishing a gradual control through dose increases on the primary tumor and metastases.
In 4 years we have been able to significantly improve Juana's quality of life, establish effective control over the myeloma to the point that she was able to have a transplant and thus eliminate the tumor, in addition the metastases disappeared.
Undoubtedly, this is an enormous result, which reflects the great potential of the LifEscozul formulation and the importance of continuing with the established trials and protocols.
We are the LifEscozul Group and the Results Define Us.
Juan José Rodríguez
Mr. Juan Jose was diagnosed with prostate cancer discovered after 3 biopsies, which were performed due to successive increases in PSA. "The diagnosis of prostate cancer is usually based on the results of a clinical examination of the prostate and a blood test in which the levels of a protein called prostate-specific antigen (PSA) are checked, as well as the results of a biopsy."The diagnosis of prostate cancer is usually based on the results of a clinical examination of the prostate and a blood test in which the levels of a protein called prostate-specific antigen (PSA) are checked, as well as the results of a biopsy. View more